12 Posts You Should Not Miss From Day 2 of ESMOGI24!
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Our team at OncoDaily has compiled a list of posts from the 2nd day of this conference that you should not miss!
The final results of the KEYNOTE-585 study presented at ESMOGI24 suggest that the current treatment standard for resectable gastric/gastro-oesophageal junction cancers should remain unchanged.
Event-free survival was not significantly improved with pembrolizumab plus chemotherapy compared to placebo plus chemotherapy or placebo plus FLOT.
According to Elizabeth Smyth however, the increase in the pathological complete response rate seen with the addition of pembrolizumab suggests it may improve response to chemotherapy in at least some patients.
To learn more about this topic, read the ESMO Daily Reporter article.
This is the football/oncology crossover I’m here for, Chiara Cremolini!
I agree KEYNOTE-177 v CheckMate 8HW is fraught with the pitfalls of cross-trial comparison (FWIW, I still favor pembro alone unless I really need a quick response making anti-CTLA4 more worthwhile).
Discussion of immunotherapy in GIT Cancer in both dMMR as well as pMMR. Great debate and new data.
New data from the NEST clinical trial was presented at ESMO‘s ESMOGI24 – results demonstrated significant tumor reductions in MSS colon cancer patients treated with botensilimab/balstilimab in the neoadjuvant setting. Learn more.
Our multicenter study found that renal dysfunction, age and Olmesartan increase the risk of severe diarrhea in colorectal cancer patients treated with CAPOX.
Peter de Gooyer from the Netherlands was awarded as the best poster presenter in rectal cancer at ESMOGI24 with the TARZAN study. Congrats to him and the team.
NEST Trial highlighted by Myriam Chalabi. Link to the ESMO Daily Reporter article. From the initial 3-4 weeks to longer brewing time of 7-8 weeks, is there an optimum duration?
“The last frontier” is IO for MSS tumors.
Hepatocellular cancer – Treatment of localised tumours by Maria Reig at ESMOGI24:
- Personalized treatment is key
- Multidisciplinary team to guide treatment
- Stage migration based on pattern of response/progression
Thank you to everyone who attended the EORTC session on hot topics and methodological perspectives in gastro-intestinal oncology trials today at ESMO GI.
For more information.
The bottom line for ICI plus perioperative chemo in gastric cancer at ESMOGI24 plenary. KN585 a negative trial but long term benefit in PDL1 high/MSI subgroups.
MATTERHORN incoming….will better chemo partner + statistical design carry it through?
Is it time for a new staging system for CRC? Addition of post-surgical ctDNA to TNM staging might better risk stratify patients.
Regardless of TNM, majority of MRD will have recurrence at 2 years, despite selective use of AC.
ESMOGI24: Updated results from the TRANSMET trial showed that chemotherapy combined with liver transplantation in highly selected patients with CRC quadrupled the 5-year OS rate VS chemotherapy alone.
Link to ESMO Daily Reporter.
